M&A: Buy-Side Transactions

The whole buy-side workflow on one sheet: capability gates, valuation, defenses, tax, credit, financing, bid sequence, execution, and the board fiduciary backdrop.

The One-Liners That Win Points

• Financial capacity is a separate test from valuation. A deal can clear the discounted-cash-flow model and still be infeasible if funding it breaches covenants, loses investment-grade rating, or over-dilutes shareholders.
• Strong currency invites stock; weak currency invites cash plus debt. A high-multiple acquirer can spend a unit of stock for a lot of target value; a low-multiple acquirer cannot.
• Trading comps set the standalone floor (minority-interest, no control premium); precedent transactions anchor the high end (control premium of 25% to 50%+ baked in).
• Terminal value drives about 75% of the discounted cash flow (DCF) output, so terminal-value assumptions drive the answer.
• The leveraged buyout (LBO) sets the strategic buyer's walkaway: a strategic who cannot beat the sponsor's maximum loses the asset.
• A friendly bid with board approval BEFORE the ownership threshold is crossed avoids all three state statutes (control-share, fair-price, business-combination).
• The reverse triangular merger is the most common modern structure because the target survives, preserving contracts and licenses.
• Indication of Interest (IOI) is a RANGE; Letter of Intent (LOI) is a POINT. An LOI is "partially binding," not non-binding (exclusivity, break fees, confidentiality bind at signing).
• A "fully financed" bid means financing is NOT a closing condition, backstopped by a committed-financing (bridge) letter.
• Targets jump; acquirers do not. Target up roughly 22% on announcement; acquirer flat to mildly negative.

Numbers to Lock In

Top Gotchas

• The poison pill trigger is BENEFICIAL ownership, not record ownership; options, derivatives, and swaps can count. The pill is defeasible: the board can redeem it, so an activist who replaces the board neutralizes a standalone pill.
• The poison pill plus staggered board combo is the strongest STRUCTURAL defense package. A pill alone can be redeemed by the next board; adding a staggered board forces two consecutive proxy contests (roughly two years).
• A control-share statute strips VOTING rights, not OWNERSHIP rights. The acquirer still holds the shares economically.
• The fair-price statute does NOT block tender offers; it blocks the LOWER back-end leg. A uniform-price offer clears it.
• The 85% business-combination calculation EXCLUDES shares owned by directors, officers, and certain employee-stock-ownership-plan (ESOP) holdings, so heavy insider ownership makes that exception harder to clear.
• Type B is strict: only voting stock of the acquirer, no cash boot at all (even one dollar blows it). Type C allows up to 20% non-voting; Type A is most flexible (about 40% continuity).
• The stock-treated-as-asset election is NOT available for a standalone C corporation (double taxation); only S corporations and consolidated-group subsidiaries qualify. It preserves the LEGAL stock-sale character, so no assignment consents.
• Revenue synergies are routinely overstated (25% to 35% capture vs 70% to 85% for cost synergies); stress-test them separately and keep them in the upside case.
• All-stock accretion / dilution flips on the RELATIVE price-to-earnings ratio, not absolute price: accretive when target earnings yield exceeds acquirer earnings yield.
• Covenant testing happens BEFORE rating-agency review in the deal sequence: facility documents are signed contracts (hard requirement); rating reactions are discretionary and forward-looking.
• Unocal and Revlon are TARGET-side duties; they shape what the buyer expects, not the buyer's own board. Revlon is triggered by sale INEVITABILITY, not a sale offer, and all-cash deals trigger it faster.

Buy-Side Strategy and Acquirer Capability

• Three independent go / no-go gates before any bid: strategy (does the target fit the stated corporate plan?), resources (internal M&A team plus external advisors plus management bandwidth?), and financial capacity (cash, revolver headroom, incremental debt within covenants and ratings, equity-issuance optionality).
• Strategic rationale and stated corporate strategy are NOT the same test. A defensive block can be valid in isolation yet clash with the public capital-allocation plan.

Acquisition Rationale and Value of the Buyer's Business

• Four rationale categories: cost synergies (most quantifiable), revenue synergies (higher upside, lower realization), strategic positioning (defensive / platform / geographic), financial engineering (multiple arbitrage, tax-attribute monetization, leverage utilization).
• "Value of the buyer's business" is the issuer-side baseline, not a target valuation. It frames the stock-versus-cash decision, drives accretion / dilution math (via the acquirer's price-to-earnings ratio and earnings yield), and tests the deal against alternative uses of capital.

Anti-Takeover Defenses and Structural Impediments

• Poison pill (shareholder rights plan): board-adopted; flip-in dilutes the acquirer, flip-over dilutes into the acquirer's own equity; board can redeem for nominal value (the negotiating lever).
• Staggered (classified) board: charter provision; directors removable only for cause under the default Delaware rule; a clock, not a sale-blocker.
• Control-share statute: strips voting rights above thresholds pending a disinterested-shareholder vote; the United States Supreme Court upheld the Indiana statute.
• Fair-price statute: neutralizes coercive two-tier tender offers by requiring a fair-price back-end or a supermajority disinterested vote.
• Business-combination statute (Delaware model): 3-year freeze after crossing 15%, unless board pre-approval, 85%-or-more sweep, or a two-thirds disinterested vote; default applies, companies opt out.
• The state statutes apply only to non-board-sanctioned transactions; a friendly bid with prior board approval avoids all three.

Tax Considerations

• Tax deferral applies only to the stock portion; boot (cash / non-stock) is taxable. The acquirer takes carryover basis (gives up future depreciation / amortization) in a tax-free deal.
• Four continuity tests: continuity of ownership interest, continuity of business enterprise, valid business purpose, step-transaction compliance.
• Named reorganizations: Type A (statutory merger, most flexible, about 40% stock), Type B (stock-for-stock, voting stock only, 80%+ control), Type C (stock-for-assets, up to 20% non-voting boot), Type D (divisive spin-off / split-off / split-up), Type E (recapitalization), plus forward (target dissolves into subsidiary) and reverse triangular mergers (target survives, 80%+ voting stock).
• Stock-treated-as-asset election: joint buyer-seller election giving the buyer a stepped-up basis; S corporations and consolidated-group subsidiaries only; irrevocable.
• Recapitalizations (debt-for-equity, leveraged-recap dividend, equity-for-debt) can qualify as Type E.

Target Analysis

• Six lenses: financial results, future prospects, market position, industry dynamics, strategic value to the buyer, potential synergies.
• Financial results lean on quality-of-earnings analysis, the margin stack, and return metrics; future prospects build base / upside / downside cases off management projections.
• Strategic value to the buyer is BUYER-SPECIFIC: two bidders see different value in the same target, which is the dominant source of bid dispersion.
• Synergies split into cost (70% to 85% capture), revenue (25% to 35%, overstated), and financial (net-operating-loss monetization, lower combined cost of capital).

Valuation Methods

• Trading comparables: peer multiples (enterprise value to EBITDA, to sales, to EBIT; price-to-earnings) → standalone equity value floor, no control premium.
• Precedent transactions: historical deal multiples → control-bid benchmark, anchors the high end.
• Discounted cash flow (DCF): free cash flow over 5 to 10 years plus terminal value at the weighted-average cost of capital (WACC); terminal value is about 75% of output.
  • Perpetuity-growth method: TV = FCF_final × (1 + g) / (WACC − g)
  • Exit-multiple method: TV = EBITDA_final × exit multiple
  • Subtract net debt (debt minus cash) to get equity value.
• Leveraged buyout (LBO): sponsor-funded, mostly debt; output is the maximum price a sponsor can pay while clearing the internal-rate-of-return (IRR) hurdle; sets the strategic buyer's floor. LBO IRR is GROSS, not net to limited partners.
• Standalone sets the floor; pro-forma (target + buyer + synergies − integration cost) sets the ceiling; the deal is negotiated inside the spread.
• Accretion / dilution: Pro-forma EPS = (acquirer net income + target net income + after-tax synergies − after-tax financing cost) / pro-forma share count.

Credit Implications and Pro-Forma Leverage

• Three pro-forma metrics: total debt / EBITDA, EBITDA / interest (coverage), and funds from operations (FFO) / debt.
• Rating agencies react in two stages; pro-forma leverage above 4.0x can trigger an investment-grade-to-high-yield downgrade, shrinking the investor base and stepping up borrowing cost.
• A credible deleveraging plan (a 2 to 3 year glide path) can buy a grace period, but one built on aspirational revenue synergies is not credible.
• Covenant testing comes before rating-agency review: existing maintenance covenants (maximum debt to EBITDA, minimum interest coverage, minimum net worth) are tested pro-forma; a breach needs an amendment or a refinancing.

Financing Alternatives

• The stack, cheapest to most expensive: cash and revolver → bridge loan → term loan B (senior secured, 7-year, covenant-lite) → senior unsecured bonds → high-yield bonds → mezzanine / second lien → convertibles → equity issuance (follow-on / private investment in public equity) → stock consideration → seller financing / earn-outs / contingent value rights.
• The committed-financing (bridge commitment) letter is the bid's closing-certainty proof; a fully committed bid removes financing as a closing condition.
• Bridge loans are MEANT to be refinanced into permanent take-out before or shortly after closing.
• Stock consideration triggers an acquirer-shareholder vote at 20% dilution under listing rules, plus a merger-registration statement.

Execution of the Deal

• Follow-up due diligence sharpens the bid; findings (working-capital deficit, quality-of-earnings shortfall, off-balance-sheet liabilities, customer concentration) drive price adjustments, escrows, earn-outs, or walkaway.
• Final bid review updates valuation, accretion / dilution, and financing, then formalizes the binding-bid letter.
• Fairness-opinion prep is HAND-OFF work, not a banker decision: the banker briefs the independent fairness committee; the opinion supports the buyer board's business-judgment-rule defense.
• The buy-side banker is the principal FINANCIAL-TERMS interface to the acquirer's legal counsel and accountants (purchase price, consideration mix, working-capital adjustment, escrow, earn-outs, financing triggers), not the legal drafter.

Board Fiduciary Backdrop for the Buyer

• Business-judgment rule is the default: informed, disinterested, good-faith board decisions get judicial deference; the banker's valuation work and fairness opinion establish the "informed" prong.
• Unocal (enhanced scrutiny of target defensive measures) and Revlon (target's duty to maximize price once a sale is inevitable) are Delaware case law, not statutes, and apply to Delaware-incorporated targets.
• Both are target-side duties the buyer reads as a diagnostic: Unocal predicts defensive posture; Revlon predicts price-maximization posture (and constrains exclusivity, break-fee, and no-shop terms).

One-Breath Recap

Before pricing anything, the buy-side banker gates the deal on whether the acquirer can execute it (strategy, resources, financial capacity), because a deal can clear valuation and still be unfundable. The target is valued four ways: trading comps set the standalone floor, precedent transactions anchor the high end with a 25% to 50%+ control premium, discounted cash flow triangulates intrinsic value (terminal value drives about 75% of it), and the leveraged buyout sets the strategic buyer's walkaway. In parallel the banker diagnoses anti-takeover defenses (a friendly bid with prior board approval sidesteps the control-share, fair-price, and 15%/3-year business-combination statutes), designs tax structure (the reverse triangular merger preserves contracts; tax deferral rides only the stock portion), and clears the acquirer's credit framework before arranging committed financing. It all converges into a two-step bid: a non-binding Indication of Interest range, then a partially binding Letter of Intent, delivered inside the Delaware business-judgment / Unocal / Revlon backdrop that shapes how the target board will respond.

Need more than the recap? This is a condensed summary. If it is not enough, read the full M&A: Buy-Side Transactions unit for the complete lesson.